The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global joint reconstruction devices market reached a value of US$ 24.42 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 34.85 Billion by 2027, exhibiting a CAGR of 5.60% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Joint reconstruction devices are primarily designed for restoring the movement of joints, providing them with structural support either temporarily or permanently, or aiding in tissue reconstruction. These devices are utilized separately or together with one or more implantable medical devices as a replacement in whole or part for shoulder, hip, or knee joints. Nowadays, joint disorders like osteoarthritis (OA) are widely becoming prevalent on account of sedentary lifestyles and unhealthy dietary patterns of individuals. This is positively influencing the requirement for joint reconstruction devices across the globe.
The rising geriatric population around the world represents one of the key factors stimulating the growth of the market. Moreover, the advent of advanced, emerging technologies, such as 3D printing, robotics, and augmented reality (AR), are making joint reconstruction safer, more accurate, and efficient. 3D printing is increasingly being used in creating customized bio models (replicas of patient anatomy), devices, and implants to plan and simulate complex surgical procedures. This technology facilitates joint replacements associated with infection or the failure of a previous replacement joint. Besides this, robotic-assisted surgery is emerging as an innovative method for hip and knee arthroplasty as it offers enhanced component positioning, real-time information about soft tissue tensioning and balance, and restoration of hip length and offset. This, coupled with the increasing accidental or sports-related injuries that cause broken bones and dislocations, is strengthening the growth of the market. Apart from this, there is a rise in the number of individuals requiring total ankle replacement (TAR) and tibiotalar arthrodesis (TTA) for the surgical management of ankle arthritis, which is projected to drive the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global joint reconstruction devices market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on technique, joint type and end user.
Breakup by Technique:
Breakup by Joint Type:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aesculap Inc. (B. Braun Melsungen AG), Conformis Inc., Conmed Corporation, DJO Global Inc. (Enovis Corporation), Exactech Inc., Johnson & Johnson Services Inc, Kyocera Medical Technologies Inc. (Kyocera Corporation), Medacta International SA, Smith & Nephew plc, Stryker Corporation and Zimmer Biomet.
|Base Year of the Analysis||2021|
|Segment Coverage||Technique, Joint Type, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Aesculap Inc. (B. Braun Melsungen AG), Conformis Inc., Conmed Corporation, DJO Global Inc. (Enovis Corporation), Exactech Inc., Johnson & Johnson Services Inc, Kyocera Medical Technologies Inc. (Kyocera Corporation), Medacta International SA, Smith & Nephew plc, Stryker Corporation and Zimmer Biomet.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at